For the Inventor, By the Inventor

Enter assignee name

Perseus Proteomics Inc.

USPTO Granted Patents = 27

% Expired Patents = 51.9

CIPO Patents = 2

EPO Patents = 16

Forward Citations = 63

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

Hiroyuki Aburatani (12 out of 27 patents)

Katsuyuki Mitomo (8 out of 9 patents)

Hiroko Iwanari (8 out of 10 patents)

4. Katsushi Kouda (7 out of 7 patents)

5. Yukio Ito (6 out of 87 patents)

6. Takao Hamakubo (6 out of 17 patents)

7. Keisuke Ishii (5 out of 28 patents)

8. Yoko Kayukawa (5 out of 5 patents)

9. Fumiko Nomura (5 out of 5 patents)

10. Yoshitaka Hippo (5 out of 6 patents)

11. Lilin Zhang (5 out of 5 patents)

12. Tatsuhiko Kodama (4 out of 31 patents)

13. Hirotaka Ito (4 out of 25 patents)

14. Gene Kurosawa (4 out of 7 patents)

15. Yoshikazu Kurosawa (4 out of 13 patents)

Core Competencies:

Cancer Diagnosis

Anti-CDH3 Antibody

Drug Conjugate

Therapeutic Agents

Gene Overexpression

Transferrin Receptor

PTX3 Measurement

Tumor Diagnostic Agent

ROBO1 Antibody

Alzheimer's Disease

Cell Membrane Surface Antigen

Monoclonal Antibody

27 patents: Sort by Forward Citations

1. 12752008 - Composition containing buffer (2026-10-06),

2. 11951168 - Composition containing buffer (2024-04-09),

3. 10030071 - Antibody which specifically reacts with human integrin A6B4 (2018-07-24),

4. 9764041 - Drug conjugate comprising anti-CDH3 (P-cadherin) antibody (2017-09-19),

5. 9644029 - Cancer diagnosis and treatment of cancer using anti-ROBO1 antibody (2017-05-09),

6. 9644028 - Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof (2017-05-09),

7. 9598496 - Antibody capable of specifically recognizing transferrin receptor (2017-03-21),

8. 9593165 - Antibody capable of specifically recognizing transferrin receptor (2017-03-14),

9. 9513292 - Method for diagnosing cancer by detecting GPC3 (2016-12-06),

10. 9434775 - Gene overexpressed in cancer (2016-09-06),

11. 9376475 - Gene overexpressed in cancer (2016-06-28),

12. 9328160 - Anti-CDH3 antibody having high internalization capacity (2016-05-03),

13. 9273140 - Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D (2016-03-01),

14. 9155805 - Monoclonal antibody, and use thereof (2015-10-13),

15. 9127061 - Anti-human P-cadherin (CDH3) recombinant antibody (2015-09-08),

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, specializing in advanced proteomics solutions. The organization focuses on the development of innovative technologies for protein analysis, enabling researchers to gain deeper insights into biological processes and disease mechanisms. By leveraging cutting-edge methodologies, Perseus Proteomics aims to enhance the understanding of protein functions and interactions, contributing to advancements in drug discovery and personalized medicine.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

27 Patents

#1,136 in Tokyo

#2,454 in Japan

#23,984 in the World

Perseus Proteomics Inc.

Forward Citations = 63

70 inventors:

Hiroyuki Aburatani (12 out of 27 patents)

Katsuyuki Mitomo (8 out of 9 patents)

Hiroko Iwanari (8 out of 10 patents)

4. Katsushi Kouda (7 out of 7 patents)

5. Yukio Ito (6 out of 87 patents)

Please report any incorrect information to [email protected]

Loading…